NeuBase Therapeutics, Inc.

DB:O7P Rapporto sulle azioni

Cap. di mercato: €1.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NeuBase Therapeutics Gestione

Gestione criteri di controllo 1/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Todd Branning

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO2.4yrs
Proprietà del CEO0.04%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione3.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Todd Branning rispetto agli utili di NeuBase Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

Compensazione vs Mercato: Insufficient data to establish whether Todd's total compensation is reasonable compared to companies of similar size in the German market.

Compensazione vs guadagni: Insufficient data to compare Todd's compensation with company performance.

AMMINISTRATORE DELEGATO

Todd Branning (54 yo)

2.4yrs

Mandato

US$922,445

Compensazione

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Dietrich Stephan
Founder4.9yrsUS$1.15m6.14%
€ 78.5k
Dov Goldstein
Independent Chairperson4.9yrsUS$74.42k0.040%
€ 510.9
Eric Richman
Independent Director4.9yrsUS$68.38k0.060%
€ 765.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board1.1yrsNessun datoNessun dato
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.7yrsNessun datoNessun dato
James Coull
Member of Gene Editing Advisory Board1.1yrsNessun datoNessun dato
Randy Davis
Member of Scientific Advisory Board3.6yrsNessun datoNessun dato
Danith Ly
Member of Advisory Boardno dataNessun datoNessun dato
Robert Friedlander
Chair of Scientific Advisory Boardno dataNessun datoNessun dato
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.7yrsNessun datoNessun dato
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.6yrsNessun datoNessun dato
Gerald Mcdougall
Independent Director3.1yrsUS$59.79k0%
€ 0

3.6yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: O7P's board of directors are considered experienced (3.6 years average tenure).